TY - JOUR AU - Augustine, E. F. AU - Adams, H. R. AU - Mink, J. W. PY - 2013 DA - 2013// TI - Clinical trials in rare disease: challenges and opportunities JO - J Child Neurol VL - 28 UR - https://doi.org/10.1177/0883073813495959 DO - 10.1177/0883073813495959 ID - Augustine2013 ER - TY - STD TI - Eichler H-G, Bloechl-Daum B, Bauer P, Bretz F, Brown J, Hampson L, et al. “ Threshold-crossing ” : a useful way to establish the counterfactual in clinical trials? 2016;0:1–14. ID - ref2 ER - TY - STD TI - Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9. ID - ref3 ER - TY - BOOK PY - 2006 DA - 2006// TI - Guideline on clinical trials in small populations ID - ref4 ER - TY - JOUR AU - Sibbald, B. AU - Roland, M. PY - 1998 DA - 1998// TI - Why are randomised trials important ? JO - Br Med J VL - 316 UR - https://doi.org/10.1136/bmj.316.7126.201 DO - 10.1136/bmj.316.7126.201 ID - Sibbald1998 ER - TY - JOUR AU - Haffner, M. E. AU - Whitley, J. AU - Moses, M. PY - 2002 DA - 2002// TI - Two decades of orphan product development JO - Nat Rev Drug Discov VL - 1 UR - https://doi.org/10.1038/nrd919 DO - 10.1038/nrd919 ID - Haffner2002 ER - TY - JOUR AU - Kutler, D. I. AU - Auerbach, A. D. AU - Satagopan, J. AU - Giampietro, P. F. AU - Batish, S. D. AU - Huvos, A. G. PY - 2003 DA - 2003// TI - High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia JO - Arch Otolaryngol Head Neck Surg VL - 129 UR - https://doi.org/10.1001/archotol.129.1.106 DO - 10.1001/archotol.129.1.106 ID - Kutler2003 ER - TY - STD TI - Miller K, Wuertz B, Ondrey FG. Pioglitazone and metformin as potential chemopreventative treatments in Fanconi anemia related oral squamous carcinoma [abstract]. Proc. 106th Annu. Meet. Am. Assoc. Cancer Res. Philadelphia; 2015. p. Abstract nr 914. ID - ref8 ER - TY - STD TI - National Cancer Institute (NCI). Pioglitazone for Oral Premalignant Lesions. https://clinicaltrials.gov/ct2/show/NCT00951379. Accessed 23 Nov 2016. UR - https://clinicaltrials.gov/ct2/show/NCT00951379 ID - ref9 ER - TY - JOUR AU - Jepsen, P. AU - Johnsen, S. AU - Gillman, M. AU - Sorensen, H. PY - 2004 DA - 2004// TI - Interpretation of observational studies JO - Heart VL - 90 UR - https://doi.org/10.1136/hrt.2003.017269 DO - 10.1136/hrt.2003.017269 ID - Jepsen2004 ER - TY - JOUR AU - Billingham, L. AU - Malottki, K. AU - Steven, N. PY - 2016 DA - 2016// TI - Research methods to change clinical practice for patients with rare cancers JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00396-4 DO - 10.1016/S1470-2045(15)00396-4 ID - Billingham2016 ER - TY - JOUR AU - Griggs, R. C. AU - Batshaw, M. AU - Dunkle, M. AU - Gopal-Srivastava, R. AU - Kaye, E. AU - Krischer, J. PY - 2009 DA - 2009// TI - Clinical research for rare disease: opportunities, challenges, and solutions JO - Mol Genet Metab VL - 96 UR - https://doi.org/10.1016/j.ymgme.2008.10.003 DO - 10.1016/j.ymgme.2008.10.003 ID - Griggs2009 ER - TY - JOUR AU - Mendell, J. R. AU - Goemans, N. AU - Lowes, L. P. AU - Alfano, L. N. AU - Berry, K. AU - Shao, J. PY - 2016 DA - 2016// TI - Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy JO - Ann Neurol VL - 79 UR - https://doi.org/10.1002/ana.24555 DO - 10.1002/ana.24555 ID - Mendell2016 ER - TY - JOUR AU - Chalmers, T. C. PY - 1975 DA - 1975// TI - Randomization of the first patient JO - Med Clin North Am VL - 59 UR - https://doi.org/10.1016/S0025-7125(16)32001-6 DO - 10.1016/S0025-7125(16)32001-6 ID - Chalmers1975 ER - TY - JOUR AU - Simon, R. AU - Blumenthal, G. M. AU - Rothenberg, M. L. AU - Sommer, J. AU - Roberts, S. A. AU - Armstrong, D. K. PY - 2015 DA - 2015// TI - The role of nonrandomized trials in the evaluation of oncology drugs JO - Clin Pharmacol Ther VL - 97 UR - https://doi.org/10.1002/cpt.86 DO - 10.1002/cpt.86 ID - Simon2015 ER - TY - JOUR AU - Prasad, V. AU - Oseran, A. PY - 2015 DA - 2015// TI - Do we need randomised trials for rare cancers? JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.04.015 DO - 10.1016/j.ejca.2015.04.015 ID - Prasad2015 ER - TY - JOUR AU - Gaddipati, H. AU - Liu, K. AU - Pariser, A. AU - Pazdur, R. PY - 2012 DA - 2012// TI - Rare cancer trial design: lessons from FDA approvals JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1135 DO - 10.1158/1078-0432.CCR-12-1135 ID - Gaddipati2012 ER - TY - BOOK PY - 2014 DA - 2014// TI - Assessment and analysis of studies on rare diseases. Comm. No. MB13-01 ID - ref18 ER - TY - JOUR AU - Bauer, P. AU - Kohne, K. PY - 1994 DA - 1994// TI - Evaluation Of experiments with adaptive interim analyses JO - Biometrics VL - 50 UR - https://doi.org/10.2307/2533441 DO - 10.2307/2533441 ID - Bauer1994 ER -